VARIBAR HONEY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VARIBAR HONEY (VARIBAR HONEY).
Barium sulfate is a radiopaque agent that absorbs x-rays, providing contrast in the gastrointestinal tract by coating the mucosal surface.
| Metabolism | Not metabolized; excreted unchanged in feces. |
| Excretion | Not applicable. VARIBAR HONEY is a non-absorbed barium sulfate suspension for oral or rectal administration. It is eliminated via fecal route: 100% unchanged in stool after gastrointestinal transit. No renal or biliary excretion occurs because the agent is not absorbed systemically. |
| Half-life | Not applicable. As a non-absorbed contrast agent, it does not have a systemic half-life. The gastrointestinal transit time is approximately 1-2 hours for small bowel follow-through and up to 24 hours for colonic transit. Clinical relevance: absence of systemic absorption precludes elimination half-life. |
| Protein binding | Not applicable. Barium sulfate is a non-absorbed, water-insoluble crystalline compound. It does not bind to plasma proteins because it remains within the gastrointestinal lumen and is not absorbed into the bloodstream. |
| Volume of Distribution | Not applicable. As a non-absorbed agent, it does not partition into body compartments. The volume of distribution is effectively the gastrointestinal lumen volume (approximately 3-5 L in adults). No systemic distribution occurs. |
| Bioavailability | Not applicable. Barium sulfate is not absorbed from the gastrointestinal tract; therefore, systemic bioavailability is 0% by both oral and rectal routes. The agent acts locally within the gastrointestinal lumen and is not intended for systemic absorption. |
| Onset of Action | Oral administration: Radiopacification of the gastrointestinal tract begins immediately upon ingestion, with visualization of the esophagus within seconds, stomach within 1-2 minutes, and small bowel within 15-30 minutes. Rectal administration: Colonic opacification is observed immediately after instillation (within 1-2 minutes). |
| Duration of Action | Oral administration: Gastrointestinal opacification persists for 1-2 hours during small bowel follow-through; colonic opacification may last up to 24 hours if retained. Rectal administration: Colonic opacification lasts for the duration of the enema (typically 15-30 minutes) and until evacuation; residual coating may persist for 1-2 hours post-evacuation. Clinical note: Duration is determined by gastrointestinal motility and the type of study (e.g., upper GI, small bowel follow-through, barium enema). |
Not applicable. Varibar Honey is a barium sulfate suspension for oral administration used as a contrast agent for GI imaging. No systemic dose; administered orally as directed by radiologist, typically 15-30 mL.
| Dosage form | SUSPENSION |
| Renal impairment | No adjustment necessary as barium sulfate is not absorbed systemically. |
| Liver impairment | No adjustment necessary as barium sulfate is not metabolized by the liver. |
| Pediatric use | Dose based on age and weight per institutional protocol; typically 5-15 mL orally for children. |
| Geriatric use | No specific adjustment required; use caution with aspiration risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VARIBAR HONEY (VARIBAR HONEY).
| Breastfeeding | Barium sulfate is not absorbed systemically after oral administration; therefore, excretion into breast milk is negligible. M/P ratio not applicable. Considered compatible with breastfeeding; use during lactation is not contraindicated. |
| Teratogenic Risk | VARIBAR HONEY contains barium sulfate, a non-absorbable radiopaque contrast agent. No human data on teratogenicity; animal studies not available. Barium sulfate does not cross the placenta in significant amounts due to lack of absorption. Fetal exposure is minimal; theoretical risk of fetal hypoxia if aspiration occurs. No specific trimester risks identified. |
■ FDA Black Box Warning
None
| Serious Effects |
Suspected gastrointestinal perforation; known or suspected intestinal obstruction; hypersensitivity to barium sulfate; concomitant use with drugs that increase risk of aspiration (e.g., sedatives, anesthetics).
| Precautions | Risk of aspiration pneumonitis if aspirated into lungs; intestinal obstruction or perforation; careful use in patients with suspected gastrointestinal obstruction, perforation, or high risk of aspiration; hydration status monitoring to prevent impaction. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of aspiration, particularly in patients with swallowing disorders or altered mental status. Assess for bowel obstruction or perforation. No fetal monitoring required. |
| Fertility Effects | No known effects on human fertility due to lack of systemic absorption. |